VA awards McKesson Corporation $1.09B for pharmaceutical prime vendor services in January 2026

Contract Overview

Contract Amount: $1,087,989,766 ($1.1B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2026-01-01

End Date: 2026-01-31

Contract Duration: 30 days

Daily Burn Rate: $36.3M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $1.09 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY Key points: 1. Contract value represents a significant portion of annual pharmaceutical spending. 2. Sole awardee suggests potential for limited competition dynamics. 3. Fixed-price contract type may offer cost certainty but could limit flexibility. 4. Short 30-day duration for this specific order. 5. Focus on pharmaceutical preparation manufacturing indicates a specialized service. 6. Geographic focus on Texas for this delivery order.

Value Assessment

Rating: good

The contract value of over $1 billion for a single month of pharmaceutical prime vendor services is substantial. Benchmarking against similar large-scale pharmaceutical contracts would be necessary for a precise value-for-money assessment. However, given the scale and essential nature of pharmaceutical supply, this award appears to be within a reasonable range for a prime vendor supporting a large federal agency like the VA. The firm fixed-price structure provides predictability for the government.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. The data does not specify the number of bidders, but the fact that McKesson Corporation was the sole awardee for this particular delivery order suggests that they were the most advantageous offer. Further analysis would be needed to understand the competitive landscape for the overall Pharmaceutical Prime Vendor program.

Taxpayer Impact: Full and open competition generally benefits taxpayers by fostering a competitive environment that can lead to better pricing and service quality. Even with a single awardee for this order, the initial competition process is designed to ensure the government secures the best value.

Public Impact

Veterans receiving essential medications through the VA healthcare system. Ensures a consistent and reliable supply chain for pharmaceuticals. Supports the operational readiness of VA medical facilities nationwide. Impacts the pharmaceutical distribution and logistics workforce. Geographic impact primarily focused on Texas for this specific order, but the overall program serves veterans nationally.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for over-reliance on a single prime vendor for critical pharmaceutical supplies.
Risk of price increases in future contract periods if competition diminishes.
Dependence on McKesson's supply chain resilience and inventory management.

Positive Signals

Established track record of McKesson Corporation as a major pharmaceutical distributor.
Firm fixed-price contract provides cost certainty for this delivery order.
Awarded through full and open competition, suggesting a competitive initial process.

Sector Analysis

The pharmaceutical prime vendor market is a critical segment of the healthcare industry, involving the distribution of a vast array of medications to government agencies and healthcare providers. This contract fits within the broader category of federal healthcare procurement, specifically focusing on the supply chain management of pharmaceuticals. Comparable spending benchmarks would involve analyzing the total federal expenditure on pharmaceutical distribution services across agencies like the Department of Defense and the Health Resources and Services Administration.

Small Business Impact

The provided data does not indicate any specific small business set-aside provisions for this contract. As a prime vendor contract of this magnitude, it is likely that McKesson Corporation would engage in subcontracting with various entities, potentially including small businesses, for logistical support, warehousing, or specialized delivery services. However, the direct award to a large corporation suggests limited direct opportunities for small businesses as prime contractors on this specific order.

Oversight & Accountability

The Department of Veterans Affairs (VA) has established oversight mechanisms for its procurement processes, including contract performance monitoring and financial accountability. Inspector General reports and audits are typically conducted to ensure compliance and identify any potential waste, fraud, or abuse. Transparency is generally maintained through public contract databases, although specific performance metrics and detailed spending breakdowns may not always be publicly available.

Related Government Programs

Pharmaceutical Prime Vendor Program
Federal Supply Schedule (FSS) for Medical Supplies
Department of Defense Pharmaceutical Contracts
Veterans Health Administration (VHA) Medical Support Contracts

Risk Flags

Potential for single-source dependency in future contract renewals.
Limited transparency on the number of bidders in the initial competition.
Short duration of the delivery order may indicate a need for interim services or specific project requirements.

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.09 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.09 billion.

What is the period of performance?

Start: 2026-01-01. End: 2026-01-31.

What is McKesson Corporation's historical performance and track record with the VA for pharmaceutical prime vendor services?

McKesson Corporation is a major player in the pharmaceutical distribution industry and has a long-standing relationship with the federal government, including the Department of Veterans Affairs, for providing pharmaceutical prime vendor services. Historical data indicates McKesson has been a consistent awardee for such contracts due to its extensive distribution network, inventory management capabilities, and ability to meet the demanding requirements of federal healthcare systems. While specific performance metrics for past VA contracts are not detailed here, their continued success in securing large-scale awards suggests a generally satisfactory performance record. However, like any large government contractor, they may have faced scrutiny or performance issues in specific instances, which would be detailed in VA performance evaluations or IG reports.

How does the $1.09 billion value for this single month delivery order compare to the VA's overall annual pharmaceutical spending?

The $1.09 billion value for this single 30-day delivery order represents a significant portion of the VA's pharmaceutical budget. The VA's total annual spending on pharmaceuticals is considerably higher, often in the tens of billions of dollars, encompassing a wide range of medications, medical devices, and related services. This specific award highlights the substantial cost associated with maintaining a robust and readily available supply of medications through a prime vendor model. It suggests that the VA relies heavily on such contracts to manage its complex pharmaceutical needs efficiently, ensuring that veterans have access to necessary treatments.

What are the primary risks associated with relying on a single prime vendor like McKesson for such a large volume of pharmaceuticals?

Relying on a single prime vendor like McKesson for a substantial volume of pharmaceuticals presents several risks. Firstly, there's a risk of supply chain disruption; if McKesson experiences issues such as natural disasters affecting their distribution centers, labor strikes, or internal operational problems, it could lead to critical drug shortages for the VA. Secondly, a lack of robust competition for subsequent contract renewals could lead to price escalations, as the government may have fewer alternatives. Thirdly, there's a potential for vendor lock-in, where the VA becomes highly dependent on McKesson's systems and processes, making it difficult and costly to switch vendors in the future. Finally, over-reliance could reduce the incentive for the vendor to innovate or offer more cost-effective solutions if they perceive minimal competitive threat.

What is the expected impact of this contract on the availability and cost of pharmaceuticals for veterans?

This contract is expected to ensure the consistent availability of a wide range of pharmaceuticals for veterans served by the VA. As a prime vendor, McKesson is responsible for managing inventory and distributing medications, which should streamline the supply chain and reduce the likelihood of stockouts. The firm fixed-price nature of this delivery order provides cost certainty for the VA for the specified period, protecting against unexpected price fluctuations. While the overall cost-effectiveness depends on the competitive landscape and negotiation of future contracts, this award aims to provide reliable access to medications at a predetermined price point, ultimately benefiting veterans' healthcare.

How does the 'Pharmaceutical Preparation Manufacturing' (NAICS 325412) classification influence the scope of this contract?

The North American Industry Classification System (NAICS) code 325412, 'Pharmaceutical Preparation Manufacturing,' indicates that the scope of this contract likely extends beyond simple distribution. It suggests that McKesson may be involved in activities such as packaging, formulating, or even manufacturing certain pharmaceutical preparations for the VA. This could include activities like unit-dose packaging, sterile compounding, or the preparation of customized medication kits. This classification implies a deeper level of service than a basic wholesale distribution agreement, potentially involving more complex logistical and manufacturing support tailored to the VA's specific needs.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $1,087,989,766

Exercised Options: $1,087,989,766

Current Obligation: $1,087,989,766

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline